University of Wisconsin, Madison
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Wisconsin, Madison sits in the top decile of US sponsors by registered trial count (#31 of 15,742 sponsors by registered trial count).
University of Wisconsin, Madison: 1,039 sponsored US clinical trials, 151 recruiting.
University of Wisconsin, Madison sponsors 1,039 registered US clinical trials on ClinicalTrials.gov, 151 of them currently recruiting, and 712 completed. 98 of these trials are in Phase 3-4 (later-stage) and 251 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 10 trials.
Top-decile sponsor footprint
University of Wisconsin, Madison ranks in the top decile of sponsors by registered trial count (#31 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
712 of 824 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,039 total, page 4 of 21
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
NCT02098265
10-Week Physical Activity Program for Mothers of Children With Developmental Disabilities
NCT07182071
Salvation Army Tobacco Quit Line Referral Implementation Trial
NCT06689774
An Imaging-based Quantitative Biomarker Assay for NAFLD in Children
NCT06354491
Implementation of Teleophthalmology in Urban Health Systems Study
NCT05773495
Brain Blood Flow Responses During Exercise
NCT05864950
Use of the LEVA® Pelvic Health System for Fecal Incontinence
NCT06152224
PTSD Treatment for Incarcerated Men and Women: WPP
NCT05432817
Lung Ultrasound - Prospective Study
NCT06140615
Clinic-level Implementation of mHealth to Improve HIV Viral Suppression for Patients With Substance Use Disorders
NCT06109571
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
NCT05854498
Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy
NCT05820711
A Communication Tool to Improve Communication in the ICU
NCT05780918
Preparing Older Adults for Major Surgery With Preoperative Comprehensive Geriatric Assessments
NCT06184919
Impact of Outreach on Medicaid Enrollment
NCT05433454
Cardiovascular and Neurovascular Regulation in GWI
NCT04586049
Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
NCT05816785
Brain Blood Flow Responses During Exercise: Younger Cohort
NCT06446622
Everolimus Aging Study
NCT05835999
Fluorescence-based Detection of Inflammation and Necrosis to Inform Surgical Decision-making and Enhance Outcomes
NCT05593523
Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
NCT05477823
Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder
NCT05322954
GCC Agonist Signal in the Small Intestine
NCT05107219
Blood Vessel Anatomy and Blood Flow Regulation
NCT05396287
ElderTree Via a Voice Activated Device for Managing Chronic Health Conditions (NHLBI)
NCT05240534
MSC in Patients With Xerostomia Post XRT in Head and Neck Cancer
NCT04489732
Mindfulness and Hip Preservation Surgery
NCT05335421
Multicenter Phenotype-Genotype Analysis of Vascular Stains to Optimize Treatment Utilizing Optical Coherence Tomography
NCT04772911
Improving Patient Walking During Hospitalization
NCT04479943
Split-Dose R-CHOP for Older Adults With DLBCL
NCT03943901
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
NCT04587128
Childhood Allergy and the Neonatal Environment
NCT04215783
IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
NCT03958383
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
NCT04090528
Hypofractionated Radiotherapy for Soft Tissue Sarcomas
NCT03972930
Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
NCT03725761
pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
NCT03600350
Epidemiology of Sleep-Disordered Breathing in Adults
NCT00005557
The Spiral MRI Study
NCT07167953
Family-Focused Study to Support Medication for Opioid Use Disorder
NCT07451197
Opti Gait Wearable Gait Tracker
NCT07158580
Little Lungs Study
NCT06855043
Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study
NCT07360301
Leveraging Artificial Intelligence to Prevent Vision Loss From Diabetes
NCT06763952
Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy Controls
NCT07680114
A Well-Being Intervention for People With IBS
NCT07600047
The Gut - PRO Study
NCT07413744
Liver Micro Flow - MRI
NCT07634939
Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome
NCT07218653
Methamphetamine Isomer Pharmacology in Humans
NCT06746831
What is open in the University of Wisconsin, Madison pipeline
151 recruiting of 1,039 indexed (15% open); 712 completed (69%).
Phase mix: 98 late (III/IV) vs 251 early (I/II) (early-phase heavy).
Top condition: Healthy (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Wisconsin, Madison: open-pipeline peers nationwide
Peers matched on 1,039 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
University of Wisconsin, Madison sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,039 trials (± recruiting share)
- University of Washington · 1,048 trials · 15% recruiting
- Bristol-Myers Squibb · 1,025 trials · 7% recruiting
- University of Florida · 1,106 trials · 15% recruiting
- University of North Carolina, Chapel Hill · 1,109 trials · 10% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Masonic Cancer Center, University of Minnesota · 14% recruiting · 249 trials
- ModernaTX · 14% recruiting · 90 trials
- United States Naval Medical Center, San Diego · 15% recruiting · 41 trials
- The Cleveland Clinic · 14% recruiting · 688 trials
Related
What to do with this University of Wisconsin, Madison page
1,039 registered trials is a research-attention snapshot, not an endorsement of University of Wisconsin, Madison or any single study.
- 151 of University of Wisconsin, Madison's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition University of Wisconsin, Madison studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Wisconsin, Madison pipeline card: 1,039 registered trials from official public datasets.Report a data error.